Seguimento de 2 anos de estudo de braço único | Ciltacabtageno Autoleucel, uma terapia de células T do receptor de antígeno quimérico anticélula B de maturação, para mieloma múltiplo recorrente/refratário.

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up – Journal of Clinical Oncology

Estudo original: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link para o resumo – $ para o texto completo)

Comentário no Twitter

In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM

— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022